Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A novel therapeutic approach for Helicobacter pylori infection: the bismuth-based triple therapy monocapsule
Autore:
de Boer, WA;
Indirizzi:
Ziekenhuis Bernhoven, Dept Internal Med, NL-5340 BE Oss, Netherlands Ziekenhuis Bernhoven Oss Netherlands NL-5340 BE 5340 BE Oss, Netherlands Univ Nymegen, Med Ctr, Dept Gastroenterol, Nymegen, Netherlands Univ Nymegen Nymegen Netherlands pt Gastroenterol, Nymegen, Netherlands
Titolo Testata:
EXPERT OPINION ON INVESTIGATIONAL DRUGS
fascicolo: 8, volume: 10, anno: 2001,
pagine: 1559 - 1566
SICI:
1354-3784(200108)10:8<1559:ANTAFH>2.0.ZU;2-E
Fonte:
ISI
Lingua:
ENG
Soggetto:
PEPTIC-ULCER DISEASE; ANTIBIOTIC-RESISTANCE; QUADRUPLE THERAPY; DUODENAL-ULCER; ERADICATION THERAPY; TREATMENT REGIMENS; SUSCEPTIBILITY; METRONIDAZOLE; OMEPRAZOLE; MANAGEMENT;
Keywords:
bismuth; bismuth triple therapy; Helicide((R)); Helicobacter pylori; metronidazole; proton pump inhibitor; tetracycline; therapy;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
69
Recensione:
Indirizzi per estratti:
Indirizzo: de Boer, WA Ziekenhuis Bernhoven, Dept Internal Med, Postbus 10, NL-5340 BE Oss, Netherlands Ziekenhuis Bernhoven Postbus 10 Oss Netherlands NL-5340BE ds
Citazione:
W.A. de Boer, "A novel therapeutic approach for Helicobacter pylori infection: the bismuth-based triple therapy monocapsule", EXPERT OP I, 10(8), 2001, pp. 1559-1566

Abstract

H. pylori infection causes peptic ulcer disease and must be regarded as a serious infectious disease. Over the past two decades treatment of the infection has been a controversial issue. Treatment is purely empirical and based on combinations of two, three or four existing drugs. Antimicrobial resistance is important and an observed increase in the prevalence of resistance may change the relative importance of certain antibiotics. Bismuth-based triple therapy with bismuth, tetracycline and metronidazole is a well investigated, cheap and FDA approved regimen to cure the infection. Adding a proton pump inhibitor increases efficacy. A novel monocapsule ('Helicide (R)')that contains bismuth, tetracycline and metronidazole simplifies the regimen. This new and patient-friendly drug has been investigated in clinical studies and is expected to be released in North America in 2002.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/06/20 alle ore 09:33:38